Akari Therapeutics reports strategic advancements under CEO Abizer Gaslightwala, including AKTX-101 progress and ADC pipeline expansion.
Quiver AI Summary
Akari Therapeutics, under the leadership of CEO Abizer Gaslightwala, has made significant strategic advancements over the past year, particularly in its development of antibody drug conjugates (ADCs). The company has progressed its lead program, AKTX-101, a Trop2-targeted ADC using the novel PH1 payload, and initiated IND-enabling activities through a partnership with WuXi XDC to support upcoming clinical trials expected to start in late 2026 or early 2027. Akari has also expanded its pipeline with the introduction of AKTX-102, targeting CEACAM5-expressing tumors, and has strengthened its intellectual property with multiple patent filings. The company aims to leverage its innovative ADC platform to improve cancer treatment while also enhancing scientific understanding and collaborations within the field.
Potential Positives
- Highlights strategic progress and leadership effectiveness of Abizer Gaslightwala during his first year as CEO.
- Advancement of lead program AKTX-101 towards IND submission, supporting transition to a clinical stage biotechnology company.
- Expansion of Akari's pipeline with the introduction of AKTX-102, targeting challenging oncology targets and enhancing the company’s market position.
- Strengthening of the intellectual property estate through multiple provisional patent filings, enhancing competitive advantage in the biotech space.
Potential Negatives
- While the press release highlights strategic advancements, it also underscores that Akari Therapeutics has not yet entered clinical trials for its lead product AKTX-101, with a plan to do so only by late 2026 or early 2027, indicating a potentially lengthy time frame before any market impact can be realized.
- The reliance on partnerships for key development stages, such as the strategic manufacturing partnership with WuXi XDC for IND-enabling activities, may raise concerns about the company's self-sufficiency and control over its product development pipeline.
- There is a lack of specific data on the success of the preclinical studies and how they compare to industry standards, which might cast doubt on the robustness of the claims regarding the efficacy of the PH1 payload and its potential in the competitive oncology market.
FAQ
What are the key achievements of Akari Therapeutics under Abizer Gaslightwala's leadership?
Under Abizer Gaslightwala's leadership, Akari Therapeutics advanced its AKTX-101 program, expanded its ADC pipeline, and strengthened its scientific collaborations.
What is the main focus of Akari's ADC technologies?
Akari's ADC technologies focus on the novel PH1 payload, targeting RNA splicing for enhanced cancer treatment efficacy and immune system activation.
When does Akari plan to start the Phase 1 clinical study for AKTX-101?
Akari aims to initiate a first-in-human Phase 1 clinical study for AKTX-101 by late 2026 or early 2027, pending regulatory approval.
What makes AKTX-101 different from traditional antibody drug conjugates?
AKTX-101 uses a unique spliceosome-modulating payload, PH1, which disrupts RNA splicing in cancer cells, differing from conventional tubulin inhibitors and DNA damaging agents.
How has Akari expanded its scientific capabilities recently?
Akari expanded its scientific capabilities by strengthening its intellectual property estate and forming collaborations with leading cancer research advisors and institutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKTX Hedge Fund Activity
We have seen 10 institutional investors add shares of $AKTX stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 2,723,966 shares (+inf%) to their portfolio in Q4 2025, for an estimated $787,226
- WARBERG ASSET MANAGEMENT LLC added 308,340 shares (+inf%) to their portfolio in Q4 2025, for an estimated $89,110
- SABBY MANAGEMENT, LLC removed 179,785 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $181,582
- JANE STREET GROUP, LLC added 71,644 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20,705
- CWA ASSET MANAGEMENT GROUP, LLC added 55,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $15,894
- XTX TOPCO LTD added 49,019 shares (+inf%) to their portfolio in Q4 2025, for an estimated $14,166
- UBS GROUP AG added 32,795 shares (+54658.3%) to their portfolio in Q4 2025, for an estimated $9,477
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline
Access the Akari CEO Corner
here
TAMPA, Fla. and LONDON, March 13, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala reflecting on his first year leading the Company and the strategic progress achieved during that time.
Over the past year under Abizer Gaslightwala’s leadership, Akari Therapeutics has sharpened its strategic focus and advanced the development of its proprietary PH1 ADC payload platform. In the latest CEO Corner, Mr. Gaslightwala highlights the key scientific, operational and strategic milestones achieved as the Company positions itself to transition to a clinical stage biotechnology company.
The Company’s lead program, AKTX-101, is a Trop2-targeted ADC powered by the PH1 payload and engineered with a proprietary non-cleavable linker. Under Mr. Gaslightwala’s leadership, Akari has expanded the scientific understanding of its PH1 platform through new preclinical data presentations at leading scientific conferences, including the 2025 Society for Immunotherapy of Cancer (SITC), where the novel immuno-oncology effects of the payload were presented.
A key step toward clinical advancement came with the initiation of IND-enabling activities through a strategic manufacturing partnership with WuXi XDC, a leading global ADC development and manufacturing partner. This collaboration supports Akari’s goal of submitting an IND or CTA for AKTX-101 in late 2026 or early 2027, with plans to initiate a first-in-human Phase 1 clinical study shortly thereafter, subject to regulatory clearance.
During this period of strategic advancement, Akari also expanded its pipeline with the introduction of AKTX-102, targeting CEACAM5-expressing tumors. By combining a novel antibody construct with the PH1 payload, the Company aims to unlock one of oncology’s historically challenging targets and demonstrate the scalability of its “pipeline in a payload” strategy.
In parallel, the Company strengthened its intellectual property estate through multiple provisional patent filings covering aspects of the PH1 payload, immune system activation mechanisms, antibody design innovations and potential combination strategies. Akari also established a world-class group of scientific advisors from leading cancer research institutions to support the advancement of its platform.
The CEO Corner segment is now available here .
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn .
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]
